EUVIMEDEUVIMED entdecken
Crossref

L26/P-449 Acetaminophen use during pregnancy and children’s risk of ADHD:

R. Lindahl-Jacobsen, A. Bauer, D. Kristensen

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.783 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von R. Lindahl-Jacobsen und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question Does acetaminophen (APAP) use during pregnancy increase the risk of attention-deficit/hyperactivity disorder (ADHD) in the offspring? Summary answer Maternal acetaminophen use during pregnancy was associated with an approximately 60% higher risk of ADHD in children. What is known already Several studies have reported an association between maternal acetaminophen use during pregnancy and an increased risk of ADHD in offspring, but the relationship remains debated. Such findings are challenged by potential confounding (e.g. maternal illness requiring APAP or genetic factors) and by recall bias in studies relying on self-reported medication use. Moreover, a large sibling-controlled study observed no association after adjusting for family factors, but its validity was questioned given the very low recorded APAP use (∼7.5%) in that cohort, suggesting exposure misclassification that could mask true effects. Study design, size, duration This was a historical nationwide cohort study in Denmark spanning 30 years. It included nearly 1.85 million births from 1994–2021, with children followed for ADHD diagnoses until 2024. Participants/materials, setting, methods Participants were all singleton children born in Denmark from 1994–2021 (∼1.64 million births). Maternal APAP exposure was defined by redeemed prescriptions during pregnancy, with symphysis pubis dysfunction (SPD, a pregnancy-related pelvic pain unrelated to ADHD) used as a proxy indication for analgesic use. Offspring ADHD was identified via registry records (ADHD medication prescriptions and/or hospital diagnoses). We performed within-mother sibling comparisons and propensity score–matched analyses (restricted to firstborns) to control for familial and indication-related confounding. Main results and the role of chance Among ∼907,000 firstborn children, 1.5% were prenatally exposed to APAP, which conferred a ∼60% higher ADHD risk (hazard ratio [HR] 1.60, 95% confidence interval 1.39–1.83). In sibling comparisons, an ADHD diagnosis in one child predicted a greatly increased ADHD risk in their sibling (relative risks ∼6.6 and ∼6.2 by birth order), indicating strong familial influences (e.g., diagnostic-suspicion bias). Consistently, a within-mother analysis of siblings discordant for APAP exposure showed only a modest risk increase (HR ∼1.36, 95% CI 1.23–1.51). Restricting to firstborns, maternal SPD alone was associated with elevated offspring ADHD risk (HR ∼1.40, 95% CI 1.25–1.58), and APAP use without SPD yielded a similar increase (HR ∼1.57, 95% CI 1.37–1.81); pregnancies with both SPD and APAP had the highest ADHD risk (HR ∼2.33) but with a wide CI (0.62–8.72) overlapping 1. Trimester-specific analyses showed positive associations in each exposure window, with later/persistent use carrying greater risk: first-trimester APAP use had HR ∼1.46, third-trimester use HR ∼1.86, and APAP use in all three trimesters conferred HR ∼2.23 (95% CI 1.17–4.24). The observed risk increases were statistically significant (except in the small SPD+APAP subgroup) and unlikely to be due to chance. Limitations, reasons for caution A key limitation is exposure misclassification: over-the-counter APAP use was not captured, misclassifying some users as unexposed and biasing results toward the null. Residual confounding and ADHD outcome misclassification (e.g., milder cases not captured in medication records) are also possible, all likely underestimating the true association. Wider implications of the findings Acetaminophen is widely used in pregnancy, but these findings underscore the need for more cautious use. Further research (e.g. using biomarker-confirmed exposure data) is warranted to replicate and clarify these associations and to guide evidence-based recommendations, balancing effective maternal pain management with potential neurodevelopmental risks to the child. Trial registration number No

Zitieren

APA

Lindahl-Jacobsen, R., Bauer, A., & Kristensen, D. (2026). L26/P-449 Acetaminophen use during pregnancy and children’s risk of ADHD:. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.783

Vancouver

Lindahl-Jacobsen R, Bauer A, Kristensen D. L26/P-449 Acetaminophen use during pregnancy and children’s risk of ADHD:. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.783

BibTeX
@article{LindahlJacobsen2026,
  author = {Lindahl-Jacobsen, R. and Bauer, A. and Kristensen, D.},
  title = {L26/P-449 Acetaminophen use during pregnancy and children’s risk of ADHD:},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.783}
}
Kostenlos starten →